The NHS-Galleri trial of the Galleri multi-cancer early detection test did not meet its primary endpoint of reducing combined Stage III-IV cancers. Secondary results showed a 26% reduction in Stage IV diagnoses by the third screening round for 12 deadly cancers. The test increased cancer detection rates four-fold compared to standard screening alone.
GRAIL's NHS-Galleri trial missed its primary endpoint of reducing combined Stage III and IV cancer diagnoses. However, the trial showed a 26% reduction in Stage IV diagnoses by the third screening round. Results were presented at ASCO 2026, and GRAIL stock fell following the announcement.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07639268 |
Caregivers-Patients Support to Cope With Advanced-Cancer (CASA) Pilot Study. |
ENROLLING_BY_INVITATION | NA |
| NCT06883058 |
Caregivers-Patients Support Coping With Advanced-Cancer (CASA) Intervention |
ENROLLING_BY_INVITATION | NA |
